- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07585760
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment (CAREMM-012)
A Prospective, Single-arm, Single-center, Phase II Study of BCMA/CD3 Bispecific Antibody Combined With CD38 Monoclonal Antibody in Newly Diagnosed Multiple Myeloma Patients With Renal Impairment
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Gang An, PhD & MD
- Numéro de téléphone: +86 13502181109
- E-mail: angang@ihcams.ac.cn
Lieux d'étude
-
-
-
Tianjin, Chine, 300000
- Recrutement
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
-
Contact:
- Gang An, PhD & MD
- Numéro de téléphone: 0086 13502181109
- E-mail: angang@ihcams.ac.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age 18 to 80 years.
- Newly diagnosed symptomatic multiple myeloma (NDMM) according to the International Myeloma Working Group (IMWG) criteria. Patients who have received up to 1 cycle of prior anti-myeloma therapy are allowed to enroll.
Presence of measurable disease at diagnosis, meeting at least one of the following criteria:
A.Serum M-protein ≥ 1 g/dL (> 10 g/L) measured by serum protein electrophoresis (SPEP) (for IgA or IgD myeloma, quantitative IgA or IgD levels may be used instead); OR
B.Urine M-protein ≥ 200 mg/24 hours; OR
C.If both serum and urine M-protein do not meet the above criteria, an abnormal serum free light chain (FLC) ratio (normal FLC ratio: 0.26 to 1.65) with an involved serum FLC level ≥ 100 mg/L.
- Accompanied by myeloma-related renal impairment (RI), defined as an estimated glomerular filtration rate (eGFR) < 40 mL/min (calculated using the Modification of Diet in Renal Disease [MDRD] formula). The type of renal impairment must be restricted to cast nephropathy, which can be confirmed by renal biopsy or by the investigator's clinical judgment based on light chain proteinuria. If urine albumin accounts for more than 30% of the total urine protein, a renal biopsy is mandatory to confirm cast nephropathy.
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2.
Adequate major organ function, meeting the following criteria:
A. Hematological function:
- Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L, and without receiving granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 7 days, or pegylated G-CSF within 14 days prior to testing;
- Hemoglobin ≥ 60 g/L, and without receiving whole blood or red blood cell transfusions within 7 days prior to testing;
- Platelet count ≥ 50 × 10^9/L, and without receiving whole blood, platelet transfusions, or thrombopoietin receptor agonists (TPO-RAs) within 7 days prior to testing.
B. Hepatic function:
Alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≤ 3 × ULN, and total bilirubin ≤ 2 × ULN (subjects with a history of Gilbert's syndrome are eligible if direct bilirubin ≤ 2.0 × ULN).
C. Coagulation function:
- International Normalized Ratio (INR) or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.
- No active concomitant malignancies or malignancies with an expected survival of less than 12 months.
- Willingness to participate in the study, good compliance, and ability to sign the informed consent form (ICF).
Exclusion Criteria:
- Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, amyloidosis, or secondary plasma cell leukemia.
- Central nervous system (CNS) involvement or clinical evidence of meningeal involvement.
- Severe and/or uncontrolled cardiac diseases, including: unstable angina, symptomatic congestive heart failure, myocardial infarction within 6 months prior to enrollment, severe and uncontrolled arrhythmias; or other cardiovascular/cerebrovascular diseases deemed unsuitable for study participation by the investigator.
- Presence of active infections, including: HIV positive; active Hepatitis B (HBV-DNA positive); active Hepatitis C (HCV-RNA positive); active or latent syphilis infection (Treponema pallidum antibody positive); active tuberculosis (active TB infection indicated by chest imaging or other relevant tests within the past 3 months or during the screening period); or other active infections deemed unsuitable for study participation by the investigator.
- Patients with concurrent malignancies; or severe concomitant diseases that, in the investigator's judgment, would severely compromise patient safety or interfere with study completion.
- Pregnant or lactating women.
- History of severe allergic reactions (Grade ≥ 3) or hypersensitivity to any components of the study drugs.
- Unable or unwilling to sign the informed consent form.
- Any other conditions that, in the opinion of the investigator, make the patient unsuitable for enrollment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: CM336 plus Isatuximab
Enrolled patients will receive 3 cycles of induction therapy with CM336 in combination with isatuximab.
|
CM336: Administered subcutaneously (SC) via a step-up dosing regimen, which includes a step-up dosing phase and a target dosing phase. Upon reaching the target dose, it will be administered once weekly. Isatuximab: Administered intravenously (IV) at a dose of 10 mg/kg, given weekly during Cycle 1, and every two weeks during Cycles 2 and 3. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Renal Response Rate (Minor Response or better)
Délai: At the end of Cycle 3 (each cycle is 28 days)
|
The Overall Renal Response Rate is defined as the percentage of participants who achieve a renal response of Minor Response or better (including Minor Response, Partial Response, and Complete Response) according to the International Myeloma Working Group (IMWG) criteria for renal impairment.
|
At the end of Cycle 3 (each cycle is 28 days)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Hematological Overall Response Rate (ORR)
Délai: From the first dose of CM336 through 30 days after the last dose of CM336
|
The percentage of participants who achieve a hematological response of Partial Response (PR) or better (including PR, Very Good Partial Response [VGPR], Complete Response [CR], and Stringent Complete Response [sCR]) according to the International Myeloma Working Group (IMWG) uniform response criteria.
|
From the first dose of CM336 through 30 days after the last dose of CM336
|
|
MRD Negativity Rate
Délai: At the end of Cycle 3 (each cycle is 28 days)
|
The percentage of participants who achieve MRD negativity in the bone marrow.
MRD negativity is defined by a threshold of 10^-5, assessed via Next-Generation Flow (NGF) cytometry in accordance with IMWG criteria.
|
At the end of Cycle 3 (each cycle is 28 days)
|
|
Kinetics of Serum Free Light Chain (sFLC) Reduction
Délai: From the first dose of CM336 through 30 days after the last dose of CM336
|
The rate and time to achieve a specific percentage or absolute reduction in involved serum free light chain (sFLC) levels from baseline.
|
From the first dose of CM336 through 30 days after the last dose of CM336
|
|
Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: From the first dose of CM336 through 30 days after the last dose of CM336.
|
Safety will be assessed by monitoring the incidence, nature, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs) such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), graded according to NCI CTCAE v5.0 and ASTCT criteria.
Dose interruptions, modifications, or discontinuations due to toxicity will also be recorded.
|
From the first dose of CM336 through 30 days after the last dose of CM336.
|
|
PFS
Délai: From the first dose of CM336 up to the date of first documented disease progression or death, up to approximately 24 months.
|
The time from the start of the study treatment to the date of first documented disease progression (according to IMWG criteria) or death from any cause, whichever occurs first.
|
From the first dose of CM336 up to the date of first documented disease progression or death, up to approximately 24 months.
|
|
OS
Délai: From the first dose of CM336 up to the date of death from any cause, up to approximately 24 months.
|
The time from the start of the study treatment to the date of death from any cause.
|
From the first dose of CM336 up to the date of death from any cause, up to approximately 24 months.
|
|
Rate of Renal Partial Response or Better
Délai: At the end of Cycle 3 (each cycle is 28 days)
|
Rate of renal partial response or better is defined as the percentage of participants who achieve a renal response of Partial Response or better (including Partial Response and Complete Response) according to the International Myeloma Working Group (IMWG) criteria for renal impairment.
|
At the end of Cycle 3 (each cycle is 28 days)
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Tumeurs, plasmocyte
- Troubles hémostatiques
- Paraprotéinémies
- Troubles des protéines sanguines
- Troubles hémorragiques
- Maladies hémiques et lymphatiques
- Myélome multiple
- isatuximab
Autres numéros d'identification d'étude
- IIT2026037
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .